Does a GLP-1 protocol improve VO2 max?

Relative VO2 max, the number expressed in millilitres of oxygen per kilogram of body weight per minute, almost always rises on a GLP-1 protocol because body weight sits in the denominator of that fraction. Absolute VO2 max, measured in litres of oxygen per minute, is the size of the aerobic engine itself, and it does not reliably improve. In trials that measured functional capacity directly, such as STEP-HFpEF, six minute walk distance improved by roughly 20 metres against placebo, which is a real gain in what people could do. The honest framing is that the same engine is moving a lighter load rather than the engine getting bigger.

What is the difference between relative and absolute VO2 max?

Absolute VO2 max is the total volume of oxygen the body can consume per minute, usually reported in litres per minute, and it reflects cardiac output and the oxidative capacity of working muscle. Relative VO2 max divides that figure by body weight in kilograms, which is why it is the number used to compare athletes of different sizes. Someone who loses 18 kilograms without changing anything about their heart or muscle will show a substantially higher relative VO2 max and an unchanged or slightly lower absolute value. Both numbers are correct and they answer different questions.

Should exercise intensity be set by heart rate on a GLP-1 protocol?

Heart rate zones drift upward on these protocols because GLP-1 receptor agonists raise resting heart rate by roughly 1 to 4 beats per minute in the semaglutide 2.4 mg label, and that offset carries into submaximal exercise. A session that used to sit in the middle of an aerobic zone can read a zone higher at identical external workload, which makes heart rate a moving reference point during titration. Power output on a bike, pace on flat ground, or a rating of perceived exertion are all steadier anchors during that phase. Zones based on a test performed before starting should be treated as stale rather than authoritative.

Why is fuelling long training sessions harder on a GLP-1 protocol?

GLP-1 receptor agonists slow gastric emptying, which is central to how they blunt appetite and also determines how quickly carbohydrate taken during exercise reaches the small intestine and enters circulation. A sports drink that would normally be substantially emptied within an hour can still be sitting in the stomach well past that point. That combination of delayed delivery and a reduced appetite for pre-session food is the practical reason endurance sessions past roughly 90 minutes get harder rather than easier as weight comes down. Fuelling questions during training belong with a clinician and a sports dietitian who know the protocol.

How much of the weight lost on a GLP-1 protocol comes from muscle?

Body composition substudies of full dose semaglutide have reported that roughly 39 percent of total weight lost came from lean mass, which is broadly in line with what happens during any rapid weight loss and slightly higher than the 25 percent often cited for slower dietary approaches. Lean mass is not all contractile muscle, since the figure includes water, glycogen and organ mass that shrink alongside it. Resistance training and adequate protein intake shift that ratio meaningfully in trials of caloric restriction, and the same principle is assumed to apply here. The relevance to aerobic capacity is that skeletal muscle holds the mitochondria and capillary beds that absolute VO2 max depends on.

Does a lower dose protect aerobic capacity better than a full dose?

No trial has tested that question, so there is no evidence to cite in either direction. The reasoning people offer is that a slower rate of weight loss is associated with better lean mass retention across the weight loss literature generally, and a smaller dose would be expected to produce slower loss. That is an inference from adjacent evidence rather than a finding about reduced dose GLP-1 protocols, which have not been studied as maintenance approaches at all. Anyone presenting a low dose protocol as a proven way to preserve fitness is stating something the data does not support.

How long does it take for aerobic performance to feel normal again?

Most reports of feeling flat during training cluster around the dose escalation weeks, when energy intake drops sharply and gastrointestinal symptoms are at their most common. Performance complaints tend to ease once the dose stabilises and intake settles, which in a standard schedule is somewhere past the first three to five months. That pattern is drawn from how side effects behave in trials rather than from any study that measured training quality week by week. Persistent breathlessness, unusual fatigue or a drop in capacity that does not track the titration timeline are reasons to be assessed rather than to wait.

What is worth measuring to track aerobic capacity on a protocol?

A repeatable submaximal test performed before the first dose gives a reference point that cannot be reconstructed afterward, and something as simple as a fixed distance walked or ridden at a fixed effort with heart rate and time recorded is enough. Repeating that test on the same course under similar conditions every eight to twelve weeks separates a genuine capacity change from a weight change. Recording body weight alongside it allows relative and absolute interpretations to be told apart, which is the distinction the raw number hides. None of this replaces clinical exercise testing where that is indicated.

Aerobic Capacity on a GLP-1 Protocol: Why VO2 Max Rises Without the Engine Getting Bigger

Nine months into a protocol, a watch reports that estimated VO2 max has gone from 28 to 33. Stairs are easier, the same hill takes less out of the legs, and the number on the wrist appears to confirm all of it. Then a hard interval session goes badly, and the two observations refuse to line up.

Both things are happening, and they are not in conflict. VO2 max is almost always reported as millilitres of oxygen per kilogram of body weight per minute, which makes body weight part of the measurement rather than something outside it. Take 18 kilograms out of the denominator and the number rises whether or not the heart, the lungs or the mitochondria have changed at all.

That is not a trick, and it is not nothing. Moving a lighter body is genuinely less demanding, which is why functional capacity improved in the trials that measured it. But the question of whether the aerobic engine itself got stronger is a separate question with a less comfortable answer, and it is the one that determines what happens on the interval session.

Key Takeaways

Relative VO2 max is oxygen uptake divided by body weight, so losing 18 percent of body mass raises the number by roughly 18 percent even if absolute oxygen uptake in litres per minute does not move at all.
STEP-HFpEF, published in 2023, found that semaglutide 2.4 mg improved six minute walk distance by about 21 metres against roughly 1 metre on placebo in people with obesity-related heart failure with preserved ejection fraction. The follow-up trial in participants with diabetes reported a smaller gain of about 14 metres.
SUMMIT, the tirzepatide trial in the same population, reported a six minute walk distance improvement of roughly 18 metres over placebo, so the functional gain is a class-level finding rather than one molecule.
Body composition substudies of full dose semaglutide reported that roughly 39 percent of total weight lost came from lean mass, above the 25 percent commonly cited for slower dietary weight loss. Skeletal muscle is where the mitochondria and capillary beds that support absolute aerobic capacity live.
Gastric emptying slows substantially on these protocols, so carbohydrate taken during a session reaches circulation later than it would otherwise. This is the practical reason sessions past roughly 90 minutes become harder to fuel rather than easier.
Resting heart rate rises by 1 to 4 beats per minute according to the semaglutide 2.4 mg label, and that offset carries into submaximal exercise, which makes heart rate based training zones drift upward at identical external workload.
No trial has tested whether a reduced dose protocol preserves aerobic capacity or lean mass better than an approved dose. The argument is an inference from the general weight loss literature rather than a finding.

21 m

six minute walk distance gain on semaglutide 2.4 mg in STEP-HFpEF, against about 1 metre on placebo

39%

of total weight lost coming from lean mass in full dose semaglutide body composition substudy reporting

1 to 4

beats per minute resting heart rate increase in the semaglutide 2.4 mg label, which shifts every heart rate zone

How Do Relative and Absolute VO2 Max Move in Opposite Directions?

Illustrative one year trajectory for a 100 kg person starting at 28 mL/kg/min, with relative uptake on the left axis and absolute uptake in litres per minute on the right

Relative VO2 max, mL/kg/min
Absolute VO2 max, L/min

Constructed trajectory illustrating the arithmetic rather than measured data from a specific cohort. The two lines describe the same person over the same year. One rises by roughly 16 percent, the other falls by about 5 percent, and the only reason they diverge is that body weight appears in one of them and not the other.

Why does VO2 max go up when the engine has not changed?

The denominator is doing most of the work

Relative VO2 max rises on a GLP-1 protocol primarily because body weight is the denominator of the fraction being reported. A person consuming 2.8 litres of oxygen per minute at maximum effort while weighing 100 kilograms records 28 mL/kg/min. The same person consuming the same 2.8 litres at 82 kilograms records 34. Nothing about the heart or the working muscle produced that difference.

This matters because relative VO2 max is a good predictor of how easy weight-bearing activity feels and a poor predictor of what the cardiovascular system can do in absolute terms. Walking, climbing stairs and running all require carrying body mass, so a lighter person doing those things at the same speed is working at a lower percentage of capacity. That is a real improvement in daily function and it is what most people notice first.

Absolute VO2 max is the number that describes the machinery. It depends on maximal cardiac output, haemoglobin mass, capillary density in the working muscle, and mitochondrial content, and none of those respond to weight loss on their own. They respond to training stimulus, and they shrink when the muscle holding them shrinks. Consumer wearables estimate relative VO2 max from heart rate and pace, so the number on a watch is by construction the one that weight loss inflates.

What Did Trials Measuring Walking Capacity Actually Find?

Approximate mean change in six minute walk distance in metres, drug arm versus comparator arm, with a supervised cardiac rehabilitation programme shown for scale

Active arm
Comparator

Approximate values reflecting primary trial reporting for STEP-HFpEF, STEP-HFpEF DM and SUMMIT, alongside a typical figure for a supervised twelve week rehabilitation programme drawn from the exercise literature rather than a head-to-head comparison. The rehabilitation bar is there for scale. A drug producing roughly 20 metres and a training programme producing roughly 50 are not competing interventions, and the trials that found the drug effect did not ask participants to train.

What is actually driving the fitness change?

Four contributions, pulling in different directions

The net change in exercise capacity on a GLP-1 protocol is the sum of several effects, and they do not all point the same way. Separating them explains why the same person can climb stairs more easily and still lose ground on a hard effort.

Less mass to move at any given speed

Carrying less body weight lowers the oxygen cost of every weight-bearing movement, which is the single largest contributor to how much better activity feels. Walking at 5 km/h costs a fixed amount of energy per kilogram, so an 18 kilogram reduction cuts the absolute demand of that walk by nearly a fifth. This effect is immediate, requires no adaptation, and is why six minute walk distance improved in trials where nobody was prescribed exercise. It also explains why the benefit is largest in weight-bearing activity and much smaller on a bike or in a pool.

Improved cardiac loading conditions

Blood pressure falls on these protocols, and STEP-HFpEF was designed around the observation that obesity-related heart failure with preserved ejection fraction involves mechanical loading of the heart by excess adipose tissue. Reduced afterload and better diastolic filling plausibly contribute a genuine cardiac component to the functional gain in that population. The size of that contribution has not been separated from the mass effect in any trial. In people without heart failure the contribution is likely to be smaller.

Loss of contractile tissue and its mitochondria

Roughly 39 percent of the weight lost on a full dose protocol came from lean mass in body composition substudy reporting, and lean mass includes the skeletal muscle where oxidative capacity physically resides. Losing muscle reduces the total mitochondrial and capillary volume available to consume oxygen, which is a direct negative for absolute aerobic capacity. Lean mass also includes water, glycogen and organ tissue, so the figure overstates pure contractile loss. It does not overstate it enough to dismiss.

A training stimulus that quietly shrinks

Energy intake drops sharply during dose escalation and gastrointestinal symptoms are most common in the same window, which tends to reduce both the volume and the intensity of training without anyone deciding to reduce it. Weeks of lighter sessions produce measurable detraining in exactly the qualities that absolute VO2 max depends on. This is the most modifiable contribution on the list and the easiest to miss, because the relative number on the watch keeps rising throughout. Training logs from the titration period usually tell a different story than the fitness estimate does.

Where Does the Relative VO2 Max Gain Come From?

Constructed decomposition of a one year relative VO2 max change, millilitres of oxygen per kilogram per minute

Constructed decomposition illustrating an argument rather than a published attribution, since no study has separated these contributions. The highlighted bar is what a watch would display. More than four fifths of it comes from the top bar, which is a change in body mass rather than a change in aerobic function, and the two negative bars are the ones that show up on an interval session.

Why does fuelling a long session get harder rather than easier?

The appetite mechanism and the fuelling mechanism are the same mechanism

Delayed gastric emptying is central to how GLP-1 receptor agonists reduce appetite, and it is the same physiology that governs how quickly carbohydrate taken during exercise reaches the small intestine. Nothing absorbs while it is still in the stomach. A gel or sports drink that would normally be largely cleared within an hour can still be sitting there well past that point, which turns a routine fuelling plan into a source of gastrointestinal distress instead of energy.

Reduced appetite compounds the problem from the other direction. Pre-session meals get smaller or get skipped, muscle glycogen starts lower, and the session that used to be comfortable at 90 minutes now runs out of fuel at 60. Neither effect is a malfunction. Both are the drug doing exactly what it is designed to do, in a context the design did not have in mind.

The magnitude of gastric slowing varies considerably between individuals and tends to be most pronounced during dose escalation. There is also evidence that the slowing effect attenuates somewhat with continued exposure to some agents, which is why the picture at month one and month nine can differ. None of this is a reason to change a fuelling strategy without input from a clinician and, where endurance training volume is meaningful, a sports dietitian.

How Much Slower Does Carbohydrate Leave the Stomach?

Approximate percent of a 60 gram carbohydrate drink emptied from the stomach by minute, with and without a GLP-1 receptor agonist

No GLP-1 agonist
On a GLP-1 agonist

Illustrative curves reflecting the direction and rough magnitude of gastric emptying delay described in pharmacology studies rather than digitized data from one experiment, and individual variation is large. The gap at the 60 minute mark is the one that matters for training. Roughly half the carbohydrate that would normally have been delivered by then has not left the stomach yet.

What Happens to Heart Rate Training Zones?

Illustrative distribution of one steady session across heart rate zones at identical external workload, before starting and during treatment

Before starting
During treatment

Constructed illustration of a heart rate offset applied to one session rather than measured session data. The external workload is identical in both cases and only the heart rate response has shifted. Time appears to migrate into the harder zones, which is a measurement artifact rather than a change in what the session demanded, and it is the reason zones set before starting stop describing effort accurately.

How much of the weight lost comes out of muscle?

The number behind the absolute VO2 max problem

Body composition substudies of full dose semaglutide have reported that roughly 39 percent of total weight lost came from lean mass, compared with a figure often cited around 25 percent for slower dietary weight loss. Lean mass in a DXA measurement is not a synonym for contractile muscle, since it includes intracellular water, glycogen and organ tissue that all decline alongside fat. That caveat softens the number without removing the concern.

The reason this connects to aerobic capacity is anatomical. Mitochondria, capillary beds and the oxidative enzyme machinery that determine how much oxygen the body can actually use are located in skeletal muscle. Less muscle means less of all three, which is why absolute VO2 max can drift downward across a year in which relative VO2 max climbs steadily.

What shifts that ratio is well established in the general weight loss literature and not specific to these drugs. Resistance training performed two to three times weekly and protein intake at the higher end of recommendations both reduce the lean mass share of weight lost during caloric restriction. Whether the same magnitude of protection applies specifically during GLP-1 treatment has not been established in a large trial, and any training or nutrition plan alongside a prescription medication belongs in a conversation with a clinician.

What Share of Weight Lost Is Lean Mass?

Approximate percent of total weight lost attributable to lean mass, by approach, where lower is better for preserving aerobic machinery

Approximate values assembled from body composition substudy reporting and the broader caloric restriction literature rather than a single trial comparing these five approaches directly. The bottom two bars come from studies of dietary weight loss with structured training, not from trials of GLP-1 protocols with training, so treat them as the direction the evidence points rather than a result anyone has demonstrated in this setting.

What is worth tracking and discussing with a prescriber?

Six observations, none of which are a training prescription

Everything below describes information worth collecting and questions worth raising. None of it is a training or nutrition plan, and no fitness estimate from a wearable should be used to change a prescription medication. Decisions about dose, escalation pace and how exercise fits alongside these medications belong with a clinician who can see the full picture.

Record a repeatable submaximal test before the first dose

A fixed course walked or ridden at a fixed effort, with time, heart rate and body weight all recorded, takes twenty minutes and cannot be reconstructed later. Repeating it every eight to twelve weeks under similar conditions produces a comparison that means something. Without a baseline there is no way to tell a genuine capacity change from a weight change, which is exactly the distinction that matters here. This is the single most useful thing to do before starting.

Log body weight alongside every fitness estimate

A relative VO2 max figure is uninterpretable without the weight it was divided by, and wearables rarely display both together in a way that makes the relationship visible. Recording weight next to the estimate allows an approximate absolute value to be reconstructed by multiplying the two. A relative number climbing while the reconstructed absolute number falls is a specific and useful observation. It is also invisible to anyone looking only at the headline figure.

Anchor effort to power or pace during titration rather than heart rate

Heart rate zones drift upward during dose escalation because resting and submaximal heart rate both rise, so a zone based session becomes a moving target during exactly the weeks when consistency is hardest. Cycling power, running pace on flat ground and rating of perceived exertion are unaffected by the drug's chronotropic effect. Using one of those as the primary anchor and treating heart rate as secondary information keeps sessions honest. Zones can be reset once the dose has been stable for a couple of months.

Watch the titration weeks for silent training volume loss

Reduced intake and gastrointestinal symptoms tend to shrink both the length and the intensity of sessions without any deliberate decision being made, and the effect only becomes visible when weekly totals are compared. Several weeks of quietly reduced load produce measurable detraining in the qualities absolute aerobic capacity depends on. A simple weekly total of training minutes makes the pattern obvious. This is the most modifiable item on the list.

Treat sessions past 90 minutes as a specific fuelling question

Delayed gastric emptying changes when carbohydrate taken during exercise becomes available, and the standard advice built around normal emptying rates stops applying cleanly. Gastrointestinal distress during long sessions is common enough on these protocols to be worth raising rather than working around alone. A clinician and, where training volume is meaningful, a sports dietitian are the right people for that conversation. Experimenting with intake during exercise while on a medication that alters gastric motility is not a do it yourself problem.

Know which symptoms mean stop and seek assessment

Breathlessness out of proportion to effort, chest discomfort, palpitations, lightheadedness or fainting during exercise warrant prompt clinical contact rather than adjustment of a training plan. Dehydration and electrolyte disturbance are more likely on these protocols and can present during exercise as fatigue or dizziness. A drop in exercise capacity that does not track the titration timeline is a reason to be assessed rather than to train through. No wearable metric is a substitute for that assessment.

What is genuinely unresolved here?

Three gaps worth naming

Almost nobody has measured absolute VO2 max directly in this setting. The trials that reported functional gains used six minute walk distance, which is a validated and clinically meaningful endpoint and is not the same measurement as maximal oxygen uptake in a laboratory. Cardiopulmonary exercise testing with gas exchange, performed before and after treatment with body composition measured alongside, is the study that would settle the question this article is about. It has not been done at any useful scale.

The populations studied were not athletic. STEP-HFpEF and SUMMIT enrolled people with obesity and heart failure with preserved ejection fraction, where the starting functional capacity was low and the room for improvement was large. Extending a 20 metre walking gain in that population to what happens to a recreational runner or cyclist is an extrapolation across a very wide gap. Trained populations training seriously alongside these medications have essentially not been studied.

Reduced dose protocols have not been tested for any of this. The argument that a slower rate of weight loss should preserve lean mass and therefore aerobic machinery is an inference from the general weight loss literature, and it is a reasonable inference rather than a finding. No trial has examined whether a sustained dose below the approved range produces useful metabolic results, let alone whether it protects fitness. Everything in this article about mechanism applies regardless of dose, and none of it makes any particular dose an appropriate choice for any particular person.

Frequently Asked Questions

Selected References

Kosiborod MN et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. New England Journal of Medicine, 2023. STEP-HFpEF primary results including six minute walk distance.
Kosiborod MN et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. New England Journal of Medicine, 2024. STEP-HFpEF DM results.
Packer M et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. New England Journal of Medicine, 2025. SUMMIT results including functional capacity endpoints.
Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 2021. STEP 1 primary results and body composition substudy reporting.
Novo Nordisk. Prescribing information for semaglutide injection 2.4 mg, sections on increased resting heart rate and delayed gastric emptying.
Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 2022. SURMOUNT-1 primary results and body composition reporting.
Hjerresen JM and related pharmacology reporting on gastric emptying rates during GLP-1 receptor agonist treatment and attenuation with continued exposure.
Weiss EP et al. and related work on lean mass loss during caloric restriction with and without resistance exercise.
American College of Sports Medicine. Guidelines for exercise testing and prescription, on relative versus absolute oxygen uptake and six minute walk distance interpretation.
Jeukendrup AE. A step towards personalized sports nutrition, on carbohydrate delivery, gastric emptying and intestinal absorption during exercise.

This article is for general educational purposes only and does not constitute medical advice, diagnosis, treatment, a training programme, or a nutrition plan. Nothing here should be used to start, stop or adjust any medication, or to design exercise or fuelling around one, based on a fitness estimate from a wearable or any other device. GLP-1 medications are prescription drugs, and dose, escalation pace, exercise participation and any low dose or microdosing approach should be decided and monitored by a qualified healthcare provider who knows your full medical history. Nothing here is intended to diagnose, prevent, treat, or cure obesity, diabetes, heart failure, sarcopenia, or any other condition, and no low dose or microdosing approach has been shown in trials to be safe or effective or to preserve aerobic capacity or lean mass. Several charts here are constructed, approximate or illustrative rather than measured outcomes, and the trial figures cited are approximations of published reporting rather than exact values. Breathlessness out of proportion to effort, chest discomfort, palpitations, lightheadedness or fainting require prompt medical assessment. Individual results vary.

Smaller Doses. Sharper Protocols.

Metabolic health you can measure, built around a dose designed to work with your body rather than against it.

Find Your Protocol